News

Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.

Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.

Data from NORD Breakthrough Summit 2022 support the need for exacerbation prevention among patients with bronchiectasis, a rare chronic condition.

The monitoring strategy used a self-operated artificial-intelligence–enabled home monitoring system in conjunction with standard care for early detection of nAMD.

The findings indicate a discrepancy between racial and ethnic demographic data in RCTs of DME and RVO and the 2010 US Census population.

Risk factors associated with inpatient mortality, included increasing age, ulcerative colitis, IBD-related surgery, pneumonia, chronic lung disease, acute kidney injury, malnutrition, frailty, heart failure, blood transfusion, sepsis/septic shock, and thromboembolism.

PASI 100 was achieved by 28% of patients in week 4, 89% in week 12, and 68% in week 36.

When compared to an intervention system guided by a therapist, a newly-designed self care system for atopic dermatitis patients may be as helpful.

Genetic factors previously known to predispose people to hyperopia were not risk factors for clinically significant depression in the study.

At 14 week, 33% of patients in the 210 mg induction etrolizumab group were in clinical remission, compared to 29% of the placebo induction group.

Approximately 5% of nurses in Mozambique were infected with hepatitis B virus during a 3-month period in 2020.

Dr. Chopra described several key points of his Pri-Med Midwest presentation regarding the future of advances in medicine, including artificial intelligence, gut bacteria, and CRISPR technology.

Top-line data comparing 2 strains of a non-systemically absorbed drug candidate was announced this morning, with SYNB1934 expected to advance to a phase 3 clinical trial.

A study featured at CHEST 2022 investigated INCS in children with OSAS to determine if the therapy improved their symptoms, polysomnography findings, behavior, and quality of life.

New analyses suggest insomnia symptoms among older patients may play a pivotal role in the relationship between objective and self-reported cognition.

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

Study data show 64.3% of patients self-administering etripamil converted to sinus rhythm within 30 minutes compared to 31.2% on placebo.

A highlighted description of some key takeaways from presentations at Pri-Med Midwest 2022, including such topics as infectious disease, monkeypox, colorectal cancer, psoriasis, and COVID-19.

Several factors that impaired healing included former smoking and seton insertion.

The Recap of Atopic Eczema (RECAP) and Atopic Dermatitis Control Tool (ADCT) were recommended to measure eczema control.

AI-enabled retinal imaging can accurately predict CVD and death, without the need for blood tests or BP measurement, according to the findings.

Fifteen out of 17 studies in a systematic review indicated that the HRD number decreased after DME treatment.

As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.

The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

An interview with Dr. Anwuri regarding her Pri-Med Midwest presentation on treating adult plaque psoriasis.

Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.

Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.